“DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Glioblastoma in 7 Major Markets. A detailed picture of the DNX-2401 (TASADENOTUREV) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
DNX-2401 is an oncolytic adenovirus engineered specifically to infect, replicate in, and kill cancer cells to elicit an immune response. Prior clinical studies have demonstrated that DNX-2401 was well tolerated and extended survival for patients with recurrent glioblastoma. DNX-2401 is currently being evaluated in several clinical trials, including a multicenter Phase 2 study evaluating DNX-2401 with pembrolizumab for adult patients with recurrent glioblastoma. DNX-2401 has been granted PRIME and Orphan designation by the EMA, and Fast Track and Orphan designation by the FDA.
Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DNX-2401 (Tasadenoturev).
• The report contains forecasted sales for DNX-2401 (Tasadenoturev) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Glioblastoma.
• The report also features the SWOT analysis with analyst insights and key findings of DNX-2401 (Tasadenoturev).
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DNX-2401 (Tasadenoturev) Analytical Perspective by DelveInsight
• In-depth DNX-2401 (Tasadenoturev) Market Assessment
This report provides a detailed market assessment of DNX-2401 (Tasadenoturev) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
• DNX-2401 (Tasadenoturev) Clinical Assessment
The report provides the clinical trials information of DNX-2401 (Tasadenoturev) covering trial interventions, trial conditions, trial status, start and completion dates.
• In the coming years, the market scenario for Glioblastoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence DNX-2401 (Tasadenoturev) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Glioblastoma are giving market competition to DNX-2401 (Tasadenoturev) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DNX-2401 (Tasadenoturev).
• Our in-depth analysis of the forecasted sales data of DNX-2401 (Tasadenoturev) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DNX-2401 (Tasadenoturev).
• Which company is developing DNX-2401 (Tasadenoturev) along with the phase of the clinical study?
• What is the technology utilized in the development of DNX-2401 (Tasadenoturev)?
• What is the product type, route of administration and mechanism of action of DNX-2401 (Tasadenoturev)?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DNX-2401 (Tasadenoturev) development?
• What are the key designations that have been granted to DNX-2401 (Tasadenoturev)?
• What is the forecasted market scenario of DNX-2401 (Tasadenoturev)?
• What is the history of DNX-2401 (Tasadenoturev) and what is its future?
• What is the forecasted sales of DNX-2401 (Tasadenoturev) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to DNX-2401 (Tasadenoturev)?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook